期刊
LANCET NEUROLOGY
卷 14, 期 9, 页码 926-944出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(15)00153-2
关键词
-
资金
- Beaufour Ipsen Pharma
- Elan
- Lilly
- Nestle
- Pierre Fabre
- Sanofi
- Servier
- EU
- Lundeck Neuroscience Foundation
- US Alzheimer's Association
- Janssen
- US National Institute on Aging
- Toyama
- Abbott
- Abbvie
- Amgen
- Anavex
- AstraZeneca
- Biogen Idec
- Biotie
- Bristol-Myers Squibb
- Cardeus
- Cohbar
- Eisai
- Eli Lilly
- Genentech
- Ichor
- iPerian
- Lundbedc
- Medivation
- Merck
- NeuroPhage
- Novartis
- Pfizer
- Probiodrug
- Roche
- Somaxon
- Lundbeck
- MSD
- Otsuka
- Regeneron
- Biogen
- TauRx Therapeutics
- National Institute for Health Research [NF-SI-0512-10053] Funding Source: researchfish
Interventions that have even quite modest effects at the individual level could drastically reduce the future burden of dementia associated with Alzheimer's disease at the population level. In the past three decades, both pharmacological and lifestyle interventions have been studied for the prevention of cognitive decline or dementia in randomised controlled trials of individuals mostly aged older than 50-55 years with or without risk factors for Alzheimer's disease. Several trials testing the effects of physical activity, cognitive training, or antihypertensive interventions showed some evidence of efficacy on a primary cognitive endpoint. However, most of these trials had short follow-up periods, and further evidence is needed to confirm effectiveness and establish the optimum design or dose of interventions and ideal target populations. Important innovations in ongoing trials indude the development of multidomain interventions, and the use of biomarker or genetic inclusion criteria. Challenges indude the use of adaptive trial designs, the development of standardised, sensitive outcome measures, and the need for interventions that can be implemented in resource-poor settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据